What We Have Learned From the Ocular Hypertension Treatment Study.
AI Summary
OHTS showed medication reduced glaucoma development in ocular hypertension patients, and a 5-factor model identifies high-risk individuals, guiding personalized treatment decisions.
Abstract
Purpose
To identify results from the Ocular Hypertension Study that can aid patients and clinicians to make evidence-based decisions about the management of ocular hypertension.
Design
Perspective.
Results
At 60 months, the cumulative frequency of developing primary open-angle glaucoma (POAG) was 4.4% in the medication group and 9.5% in the observation group (hazard ratio for medication, 0.40; 95% confidence interval [CI], 0.27-0.59; P < .0001). At 13 years the cumulative proportion of participants who developed POAG was 0.22 (95% CI 0.19-0.25) in the original observation group and 0.16 (95% CI 0.13-0.19) in the original medication group (complementary log-log x 2 P = .009). A 5-factor model (older age, higher IOP, thinner central corneal thickness, larger cup-to-disc ratio, and higher visual field pattern standard deviation) separated participants at high and low risk of developing POAG.
Conclusions
Clinicians and patients can make evidence-based decisions about the management of ocular hypertension using the risk model and considering patient age, medical status, life expectancy, and personal preference.
MeSH Terms
Shields Classification
Key Concepts4
At 60 months, the cumulative frequency of developing primary open-angle glaucoma (POAG) was 4.4% in the medication group and 9.5% in the observation group in the Ocular Hypertension Treatment Study (hazard ratio for medication, 0.40; 95% confidence interval [CI], 0.27-0.59; P < .0001).
At 13 years, the cumulative proportion of participants who developed primary open-angle glaucoma (POAG) was 0.22 (95% CI 0.19-0.25) in the original observation group and 0.16 (95% CI 0.13-0.19) in the original medication group in the Ocular Hypertension Treatment Study (complementary log-log x 2 P = .009).
A 5-factor model, including older age, higher intraocular pressure (IOP), thinner central corneal thickness, larger cup-to-disc ratio, and higher visual field pattern standard deviation, separated participants at high and low risk of developing primary open-angle glaucoma (POAG) in the Ocular Hypertension Treatment Study.
Clinicians and patients can make evidence-based decisions about the management of ocular hypertension using the risk model from the Ocular Hypertension Treatment Study and considering patient age, medical status, life expectancy, and personal preference.
Related Articles5
Clinical Application of the 20-Year Results from the Ocular Hypertension Treatment Study (OHTS)-Reply.
LetterAssociation of Systemic Medication Exposure With Glaucoma Progression and Glaucoma Suspect Conversion in the Groningen Longitudinal Glaucoma Study.
Cohort StudyApplying the recent clinical trials on primary open angle glaucoma: the developing world perspective.
ReviewRisk assessment in the management of patients with ocular hypertension.
ReviewThe impact of risk calculation on treatment recommendations made by glaucoma specialists in cases of ocular hypertension.
Observational StudyIs this article assigned to the wrong chapter(s)? Let us know.